Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

Next Previous
Search
Trial Profile

A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gepotidacin (Primary)
  • Indications Respiratory tract infections; Skin and soft tissue infections
  • Focus Adverse reactions
  • Acronyms TQT
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 18 Mar 2017 Results (n=52) assessing effects of SYM-1219 on hERG potassium channel current in vitro and QT interval, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 12 Feb 2017 Results published in the Antimicrobial Agents and Chemotherapy.
    • 14 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top